After raising $17.3 million in Series A financing in May 2011, Irvine, CA-based Ivantis has set its sights a little higher, raising $27 million for its Series B. Ivantis is working to design, develop and commercialize new technologies to treat eye diseases like glaucoma. According to a press release, the new funds “will be used to support four randomized, prospective, controlled multi-center trial at various stages around the world, including the ongoing United States trial.” The round was led by Ascension Health Ventures, with participation from New Enterprise Associates, Delphi Ventures and MemorialCare Innovation Fund.
